119 related articles for article (PubMed ID: 15289786)
1. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.
Wilkinson GR
Clin Pharmacol Ther; 2004 Aug; 76(2):99-103. PubMed ID: 15289786
[No Abstract] [Full Text] [Related]
2. Cytochromes P450 and cancer.
Kaminsky LS; Spivack SD
Mol Aspects Med; 1999; 20(1-2):70-84, 137. PubMed ID: 10575653
[No Abstract] [Full Text] [Related]
3. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
[TBL] [Abstract][Full Text] [Related]
5. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
[TBL] [Abstract][Full Text] [Related]
6. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
7. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
Sikka R; Magauran B; Ulrich A; Shannon M
Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics: has it reached the clinic?
Schwartz JB
J Gend Specif Med; 2002; 5(2):13-8. PubMed ID: 11974670
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetics and pharmacogenomics. Searching for individual antihypertensive therapy concepts].
Brand E
MMW Fortschr Med; 2003 May; 145(19):43-4. PubMed ID: 12813978
[No Abstract] [Full Text] [Related]
10. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity.
Rogers JF; Rocci ML; Haughey DB; Bertino JS
Clin Pharmacol Ther; 2003 Mar; 73(3):153-8. PubMed ID: 12621380
[No Abstract] [Full Text] [Related]
12. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics of the human cytochrome P450 monooxygenase superfamily.
Smith G; Stubbins MJ; Harries LW; Wolf CR
Xenobiotica; 1998 Dec; 28(12):1129-65. PubMed ID: 9890157
[No Abstract] [Full Text] [Related]
15. Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Gillman PK
Hum Psychopharmacol; 2005 Jan; 20(1):61-2; author reply 63-4. PubMed ID: 15614840
[No Abstract] [Full Text] [Related]
16. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.
Takahashi H; Echizen H
Pharmacogenomics J; 2003; 3(4):202-14. PubMed ID: 12931134
[No Abstract] [Full Text] [Related]
17. Cytochrome P450 pharmacogenetics and cancer.
Rodriguez-Antona C; Ingelman-Sundberg M
Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
[TBL] [Abstract][Full Text] [Related]
18. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
19. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 gene polymorphisms and risk of low birth weight.
Chen D; Hu Y; Yang F; Li Z; Wu B; Fang Z; Li J; Wang L
Genet Epidemiol; 2005 May; 28(4):368-75. PubMed ID: 15712341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
